Pathological Complete Remission in Young Colon Cancer Patient with a Large Liver Metastasis after FOLFOX-4/Bevacizumab Treatment – A Case Report


Introduction. Pathological complete remission of liver metastases is a rare colon cancer treatment outcome with increased 5-year survival of 76%. Case report. Metastatic colorectal cancer patient with pathological complete remission of large hepatic metastasis after palliative chemotherapy in combination with bevacizumab is presented. Solitary liver metastasis measuring 8 cm was observed in computed tomography (CT) scan before combined treatment. The best radiological response during treatment with FOLFOX-4 and bevacizumab therapy was partial remission and patient underwent partial hepatectomy. Since the operation material was free of viable adenocarcinoma cells the effect of FOLFOX-4 in combination with bevacizumab treatment was interpreted as the pathological complete remission. Conclusion. Use of combination chemotherapy and targeted therapy with the aim to reduce initially unresectable liver metastasis is the best option to achieve complete pathological remission and significantly prolong survival.

Share and Cite:

E. Skuja, A. Āboliņš, I. Priedīte, G. Purkalne, I. Štrumfa, J. Vilmanis, D. Kalniete, E. Miklaševičs and J. Gardovskis, "Pathological Complete Remission in Young Colon Cancer Patient with a Large Liver Metastasis after FOLFOX-4/Bevacizumab Treatment – A Case Report," International Journal of Clinical Medicine, Vol. 3 No. 4, 2012, pp. 307-310. doi: 10.4236/ijcm.2012.34061.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] E. Van Cutsem, J. Oliveira and on Behalf of the ESMO Guidelines Working Group, “Advanced Colorectal Cancer: ESMO Clinical Recommendations for Diagnosis, Treatment and Follow-Up,” Annals of Oncology, Vol. 20, No. 4, 2009, pp. iv61-iv63. doi:10.1093/annonc/mdp130
[2] L. B. Saltz, S. Clarke, E. Díaz-Rubio, W. Scheithauer, A. Figer, R. Wong, S. Koski, M. Lichinitser, T. S. Yang, F. Rivera, F. Couture, F. Sirzén and J. Cassidy, “Bevacizumab in Combination with Oxaliplatin-Based Chemotherapy as First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study,” Journal of Clinical Oncology, Vol. 26, No. 12, 2008, pp. 2013-2019. doi:10.1200/JCO.2007.14.9930
[3] R. Adam, E. Avisar, A. Ariche, S. Giachetti, D. Azoulay, D. Castaing, F. Kunstlinger, F. Levi and F. Bismuth, “Five-Year Survival Following Hepatic Resection after Neoadjuvant Therapy for Unresectable Colorectal Liver Metastases,” Annals of Surgical Oncology, Vol. 8, No. 4, 2001, pp. 347-353. doi:10.1007/s10434-001-0347-3
[4] M. Hayashi, Y. In-oue, K. Komeda, T. Shimizu, M. Asa- kuma, F. Hirokawa, Y. Miyamoto, J. Okuda, A. Takeshita, Y. Shibayama and N. Tanigawa, “Clinicopathological Analysis of Recurrence Patterns and Prognostic Factors for Survival after Hepatectomy for Colorectal Liver Metastasis,” BMC Surgery, Vol. 10, 2010, p. 27. doi:10.1186/1471-2482-10-27
[5] D. G. Blazer III, Y. Kishi, D. M. Maru, S. Kopetz, Y. S. Chun, M. J. Overman, D. Fogelman, C. Eng, D. Z. Chang, H. Wang, D. Zorzi, D. Ribero, L. M. Ellis, K. Y. Glover, R. A. Wolff, S. A. Curley, E. K. Abdalla and J. N. Vauthey, “Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point after Resection of Hepatic Colorectal Metastases,” Journal of Clinical Oncology, Vol. 25, No. 33, 2008, pp. 5344-5351. doi:10.1200/JCO.2008.17.5299
[6] R. Adam, D. A. Wicherts, R. J. de Haas, T. Aloia, F. Lévi, B. Paule, C. Guettier, F. Kunstlinger, V. Delvart, D. Azoulay and D. Castaing, “Complete Pathologic Response after Preoperative Chemotherapy for Colorectal Liver Metastases: Myth or Reality?” Journal of Clinical Oncology, Vol. 26, No. 10, 2008, pp. 1635-1641. doi:10.1200/JCO.2007.13.7471
[7] G. Y. Locker, S. Hamilton, J. Harris, J. M. Jessup, N. Kemeny, J. S. Macdonald, M. R. Somerfield, D. F. Hayes and R. C. Bast, “ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer,” Journal of Clinical Oncology, Vol. 24, No. 33, 2006, pp. 5313-5327. doi:10.1200/JCO.2006.08.2644
[8] M. J. Berends, Y. Wu, R. H. Sijmons, R. G. Mensink, T. van der Sluis, J. M. Hordijk-Hos, E. G. de Vries, H. Hollema, A. Karrenbeld, C. H. Buys, A. G. van der Zee, R. M. Hofstra and J. H. Kleibeuker, “Molecular and Clinical Characteristics of MSH6 Variants: An Analysis of 25 Index Carriers of a Germline Variant,” American Journal of Human Genetics, Vol. 70, No. 1, 2002, pp. 26-37. doi:10.1086/337944
[9] Y. Fong, J. Fortner, R. L. Sun, M. F. Brennan and L. H. Blumgart, “Clinical Score for Predicting Recurrence after Hepatic Resection for Metastatic Colorectal Cancer: Analysis of 1001 Consecutive Cases,” Annals of Surgery, Vol. 230, No. 3, 1999, pp. 309-321. doi:10.1097/00000658-199909000-00004
[10] A. Vais-man, M. Varchenko, A. Umar, T. A. Kunkel, J. I. Risinger, J. C. Barrett, T. C. Hamilton and S. G. Chaney. “The Role of hMLH1, hMSH3, and hMSH6 Defects in Cisplatin and Oxaliplatin Resistance: Correlation with Replicative Bypass of Platinum-DNA Adducts,” Cancer Research, Vol. 58, No. 16, 1998, pp. 3579-3585.
[11] W. De Roock, D. J. Jonker, F. Di Nicolantonio, A. Sartore-Bianchi, D. Tu, S. Siena, S. Lamba, S. Arena, M. Frattini, H. Piessevaux, E. Cutsem, C. J. O’Callaghan, S. Khambata-Ford, J. R. Zalcberg, J. Simes, C. S. Karapetis, A. Bardelli and S. Tejpar, “Association of KRAS p.G13D Mutation with Outcome in Patients with Chemotherapy-Refractory Metastatic Colorectal Cancer Treated with Cetuximab,” JAMA, Vol. 304, No. 16, 2010, pp. 1812- 1820. doi:10.1001/jama.2010.1535
[12] R. C. Auer, R. R. White, N. E. Kemeny, L. H. Schwartz, J. Shia, L. H. Blumgart, R. P. Dematteo, Y. Fong, W. R. Jarnagin and M. I. D’Angelica. “Predictors of a True Complete Response among Disappearing Liver Metastases from Colorectal Cancer after Chemotherapy,” Cancer, Vol. 116, No. 6, 2010, pp. 1502-1509. doi:10.1002/cncr.24912

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.